Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
11. Dose-Dense Chemotherapy Helped Patients with Metastatic Breast Cancer
(Posted: 06/05/2004) - Weekly administration of the drug Taxol® (paclitaxel) to patients with breast cancer that had spread to other parts of the body resulted in a higher response rate and a longer delay until patients' disease progressed, compared with conventional administration of the drug every three weeks.
12. Bortezomib (Velcade®) Delays Progression of Advanced Multiple Myeloma Longer than Standard Therapy
(Posted: 06/05/2004) - Early results from an international phase III trial show that bortezomib (Velcade®), a new targeted cancer drug, was more effective than standard therapy at delaying disease progression in patients with multiple myeloma that had relapsed or become resistant to other treatments.
13. Erlotinib (Tarceva®) Extends Survival in Advanced Lung Cancer
(Posted: 06/05/2004) - Erlotinib (Tarceva®) prolonged survival in patients with advanced non-small cell lung cancer who had progressed after standard chemotherapy, according to findings reported at the 2004 ASCO meeting in New Orleans.
14. Cetuximab (Erbitux®) Plus Radiation Boosts Survival for Patients with Head and Neck Cancer
(Posted: 06/05/2004) - Adding the drug cetuximab to radiation therapy can nearly double the median survival in patients with head and neck cancer that has not spread to other parts of the body, a large international phase III study has found.
15. Rituximab (Rituxan ®) Improves Response Rate in Mantle Cell Lymphoma
(Posted: 06/05/2004) - Rituximab, when added to standard chemotherapy for initial treatment of mantle cell lymphoma, shrank or eliminated tumors in a significantly higher percentage of patients than the standard chemotherapy (CHOP) alone, according to findings presented at the 2004 ASCO meeting in New Orleans.
< Previous 1 2 3 4 5 6 Next >
|
